> Details

Schnoeder, Tina M.; Schwarzer, Adrian; Jayavelu, Ashok Kumar; Hsu, Chen-Jen; Kirkpatrick, Joanna; Döhner, Konstanze; Perner, Florian; Eifert, Theresa; Huber, Nicolas; Arreba-Tutusaus, Patricia; Dolnik, Anna; Assi, Salam A.; Nafria, Monica; Jiang, Lu; Dai, Yu-Ting; Chen, Zhu; Chen, Sai-Juan; Kellaway, Sophie G.; Ptasinska, Anetta; Ng, Elizabeth S.; Stanley, Edouard G.; Elefanty, Andrew G.; Buschbeck, Marcus; Bierhoff, Holger; [...]

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: PLCG1 is required for AML1-ETO leukemia stem cell self-renewal
  • Contributor: Schnoeder, Tina M.; Schwarzer, Adrian; Jayavelu, Ashok Kumar; Hsu, Chen-Jen; Kirkpatrick, Joanna; Döhner, Konstanze; Perner, Florian; Eifert, Theresa; Huber, Nicolas; Arreba-Tutusaus, Patricia; Dolnik, Anna; Assi, Salam A.; Nafria, Monica; Jiang, Lu; Dai, Yu-Ting; Chen, Zhu; Chen, Sai-Juan; Kellaway, Sophie G.; Ptasinska, Anetta; Ng, Elizabeth S.; Stanley, Edouard G.; Elefanty, Andrew G.; Buschbeck, Marcus; Bierhoff, Holger; [...]
  • imprint: American Society of Hematology, 2022
  • Published in: Blood
  • Language: English
  • DOI: 10.1182/blood.2021012778
  • ISSN: 0006-4971; 1528-0020
  • Keywords: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>In an effort to identify novel drugs targeting fusion-oncogene–induced acute myeloid leukemia (AML), we performed high-resolution proteomic analysis. In AML1-ETO (AE)-driven AML, we uncovered a deregulation of phospholipase C (PLC) signaling. We identified PLCgamma 1 (PLCG1) as a specific target of the AE fusion protein that is induced after AE binding to intergenic regulatory DNA elements. Genetic inactivation of PLCG1 in murine and human AML inhibited AML1-ETO dependent self-renewal programs, leukemic proliferation, and leukemia maintenance in vivo. In contrast, PLCG1 was dispensable for normal hematopoietic stem and progenitor cell function. These findings are extended to and confirmed by pharmacologic perturbation of Ca++-signaling in AML1-ETO AML cells, indicating that the PLCG1 pathway poses an important therapeutic target for AML1-ETO+ leukemic stem cells.</jats:p>
  • Access State: Open Access